CSK and cancer: At this point, the amount of LIST in the cell is sufficient to prevent c‐Src Tyr530 phosphorylation by inhibiting the binding of c‐Src to CHK and CSK kinases, resulting in a continuous increase in c‐Src activity, which enhances P‐gp transport activity by modulating Cav1 phosphorylation, thereby leading to drug resistance development and malignant tumor growth (Figure 9G).